Table 3 Factors associated with higher scores in SF-36 and in EQ-VAS, by multivariable linear regression
| Â | PCS | MCS | EQ-VAS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | beta | 95%CI | p-value | beta | 95%CI | p-value | beta | 95%CI | p-value | |||
Male vs female | 16.64 | 12.71 | 20.57 |  <  0.001 | 15.53 | 11.73 | 19.33 |  <  0.001 | 10.28 | 7.12 | 13.45 |  <  0.001 |
Age, 10Â years increase | -0.66 | -2.45 | 1.12 | 0.466 | 1.38 | -0.35 | 3.10 | 0.118 | -0.32 | -1.76 | 1.12 | 0.662 |
Number of comorbidities | ||||||||||||
 1 | -7.99 | -12.75 | -3.24 | 0.001 | -4.99 | -9.59 | -0.39 | 0.033 | -4.79 | -8.62 | -0.95 | 0.015 |
 2 | -12.90 | -21.03 | -4.77 | 0.002 | -9.91 | -17.77 | -2.05 | 0.014 | -12.18 | -18.74 | -5.63 |  <  0.001 |
  ≥  3 | -27.63 | -38.76 | -16.50 |  <  0.001 | -23.78 | -34.54 | -13.02 |  <  0.001 | -17.13 | -26.10 | -8.16 |  <  0.001 |
Months from the acute phase | 0.21 | -0.06 | 0.48 | 0.125 | 0.03 | -0.23 | 0.29 | 0.817 | 0.14 | -0.08 | 0.36 | 0.204 |
Previous hospitalization | 2.50 | -2.55 | 7.55 | 0.331 | 5.67 | 0.80 | 10.55 | 0.023 | 0.62 | -3.44 | 4.69 | 0.764 |
Treatment in the acute phase | ||||||||||||
 corticosteroids | -10.18 | -15.17 | -5.18 |  <  0.001 | -6.16 | -10.99 | -1.33 | 0.012 | -5.55 | -9.58 | -1.53 | 0.007 |
 remdesivir | 3.89 | -1.96 | 9.74 | 0.192 | 3.67 | -1.99 | 9.32 | 0.203 | 3.14 | -1.57 | 7.85 | 0.191 |
 immunotherapy | -16.11 | -31.60 | -0.62 | 0.042 | -9.26 | -24.24 | 5.72 | 0.225 | -11.14 | -23.62 | 1.34 | 0.080 |
 heparin | -1.24 | -6.82 | 4.33 | 0.661 | -4.80 | -10.19 | 0.59 | 0.081 | 2.76 | -1.74 | 7.25 | 0.228 |
 NIV | 1.14 | -4.63 | 6.90 | 0.699 | 0.69 | -4.88 | 6.27 | 0.808 | -1.20 | -5.85 | 3.44 | 0.611 |